Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up – Should You Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price gapped up prior to trading on Monday . The stock had previously closed at $38.89, but opened at $43.53. Definium Therapeutics shares last traded at $41.30, with a volume of 1,762,185 shares trading hands.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: DT120 ODT achieved a second Phase 3 success in generalized anxiety disorder (GAD). Definium said the Panorama study met its primary endpoint, with statistically significant improvements in anxiety symptoms. The result strengthens the case for DT120 ODT and reduces clinical-development risk. Definium Reports Second Phase III Success in Anxiety Disorder Program
• Positive Sentiment: The company plans to discuss the results with the FDA and is targeting a regulatory filing in 2027. Successful regulatory engagement could provide the next major catalyst for DFTX. Definium Says Second Phase 3 DT120 Study Meets Goal
• Positive Sentiment: Analysts reinforced the bullish outlook: Robert W. Baird raised its price target to $79 and maintained an “outperform” rating, while HC Wainwright and Needham reiterated “buy” ratings with $70 and $66 targets, respectively. Analyst Ratings
• Neutral Sentiment: DFTX trading was halted temporarily for pending news on September 14, underscoring the significance of the trial announcement and the unusually high volatility surrounding the stock.
• Negative Sentiment: Investors may be locking in gains after DFTX’s sharp recent advance, including a prior jump of as much as 20% on the Phase 3 news. Elevated expectations can also make the stock vulnerable to selling even after favorable results.
• Negative Sentiment: Unusual options activity included purchases of 6,567 put contracts, 68% above typical daily put volume. This may signal hedging or bearish speculation, although it does not confirm a change in the company’s fundamentals.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DFTX. Robert W. Baird upped their price target on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday. Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday, June 22nd. Stifel Nicolaus boosted their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Needham & Company LLC restated a “buy” rating and set a $66.00 target price on shares of Definium Therapeutics in a report on Monday. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $75.00 target price on shares of Definium Therapeutics in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $64.88.

Definium Therapeutics Stock Performance

The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock’s fifty day moving average is $42.77 and its two-hundred day moving average is $30.62. The firm has a market capitalization of $4.95 billion, a price-to-earnings ratio of -10.73 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, analysts predict that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Insiders Place Their Bets

In other Definium Therapeutics news, CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the transaction, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at $14,435,312.13. This represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 67,119 shares of company stock worth $2,887,496. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds have recently added to or reduced their stakes in DFTX. Nykredit A S acquired a new stake in shares of Definium Therapeutics during the 2nd quarter worth about $45,000. Allworth Financial LP acquired a new position in Definium Therapeutics in the 2nd quarter valued at about $110,000. Integrated Wealth Concepts LLC acquired a new position in Definium Therapeutics in the 2nd quarter valued at about $159,000. NewEdge Advisors LLC bought a new position in Definium Therapeutics in the 2nd quarter valued at about $222,000. Finally, WINTON GROUP Ltd bought a new position in Definium Therapeutics in the 2nd quarter valued at about $240,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.